Indeed, the use of semaglutide and tirzepatide in T1D and LADA across most studies reviewed in this manuscript has been associated with a substantial reduction of daily TDD of insulin (or even with the interruption of insulin therapy), along with remarkable weight loss effects. Here, INS is linked to type 1 diabetes mellitus.